MAJOR PUBLICATIONS

Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy. Fischl MA, Olson RM, Follansbee ST, Lalezari JP, Henry DH, Frame PT, Remick SC, Salgo MP, Lin AH, Nauss-Karoi C, Lieberman J, Soo W. Annals of Internal Medicine. 1993; 118: 762-769.

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment with Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People with AIDS. Drew WL, Ives D, Lalezari JP, et al. New England Journal of Medicine. 1995;333:615-20.

Decreased HIV-1 Plasma Viremia During Antiretroviral Therapy Reflects Down regulation of Viral Replication of Lymphoid Tissue. Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi G, Pavlakis GN, Lalezari JP, Bartlett J, Steigbigel R, Cohn J, Noval R, McMahon D, Fauci AS. Proceedings National Academy of Science, 1995; 92: 6017-21.

HPMPC: Results of a Phase I/II Study of a Novel Antiviral Nucleotide Analogue. Lalezari JP, Drew WL, Glutzer E, et al. Journal of Infectious Diseases, 1995;171: 788-96.

A Randomized, Double-Blind Trial of Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDS. Spector SA, McKinley G, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien MJ. New England Journal of Medicine. 1996;334:1491-97.

Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Annals of Internal Medicine. 1997;126:257-63


A Randomized, Double-Blind Study of Cidofovir Topical Gel for Acyclovir-Resistant Herpes Simplex Virus Infections in Patients with AIDS. Lalezari JP, et al. Journal of Infectious Diseases. 1997; 176:892-99.

Selecting the Optimum Dose for a New Soft Gelatin Capsule Formulation of Saquinavir-results of a phase I/II study. Lalezari JP, et al. J Acquir Immune Defic Syndr Hum Retroviral. 1998; 19:195-6.

Safety, Pharmacokinetics, and Antiviral Activity of T-20 as a Single Agent in Heavily Pre-treated Patients. Lalezari JP, et al. (Manuscript in preparation).

The Efficacy and Safety of Inhaled Zanamivir in the Treatment of Influenza in Otherwise Helathy and "High Risk" Individuals in North America. Lalezari JP, Klein T, Stapleton et al. J Antimicrob Chemother 1999; 44(Suppl A), 42, P8.

Low-Dose Daily Subcutaneous Interleukin-2 in Combination with Highly Active Antiretroviral Therapy in HIV+ Patients: a Randomized Controlled Trial. Lalezari JP, Beal JA, Ruane PJ, et al. HIV Clinical Trials 2000;1(3) 1-15.

Zanamivir for the Treatment of Influenza A and B Infections in High Risk Patients: A Pooled analysis of Randomized Controlled Trials. Lalezari JP, Campion K, Keene O, and Silagy C. Arch of Intern Med. 2001;161:212-217.

A Comparison of Three Doses of Oral Ganciclovir Versus Intravenous Ganciclovir for Cytomegalovirus Retinitis. Lalezari JP, Friedberg D, Gioradano M, Hardy D, Drew WL, Stempien M, Robinson C, and the Syntex Cooperative Oral Ganciclovir Study Group Journal of Clinical Virology 24 (2002) 67-77.

A Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-HCMV Activity, and Safety of 1263W94 in HIV-Infected Men with Asymptomatic HCMV Shedding. Lalezari JP, Aberg J, Wang LH, et al. Antimicrobial Agents and Chemotherapy 2002;46:2969-76.

A Safety Study of Oral Valganciclovir Maintenance Treatment of CMV Retinitis. Lalezari JP, Lindley J, Walmsley S, et al. J Acquir Immune Defic Syndr. 2002; 30:392-400.

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. Lalezari JP, et al. New England Journal of Medicine 2003; 348;22